Radojković Marko, Chikunova Aleksandra, Koene Saar F, Timmer Monika, Natarajan Sivanandam V, Boyle Aimee L, Ubbink Marcellus
Department of Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
Department of Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
J Biol Chem. 2025 Jun 6;301(7):110347. doi: 10.1016/j.jbc.2025.110347.
β-Lactamase enzymes exhibit extraordinary adaptive potential, thus rendering many β-lactam drugs ineffective. The residue at Ambler position 105, also known as the gatekeeper residue, plays an important role in substrate recognition, but its implication in inhibition mechanisms remains understudied and obscure. To inspect the relationship between inhibitor-resistant phenotypes and residues at this position, we performed site-saturation mutagenesis and extensive fitness profiling of five distinct class A β-lactamases using deep sequencing. We found that inhibitor resistance is readily detectable, with variants harboring Gly or Arg being the least susceptible to inhibitors. Mutation of Ile105 to Arg in the β-lactamase BlaC simultaneously enhances activity for carbenicillin and the ability to evade clavulanic acid inhibition. The Y105G substitution in two clinically important enzymes, CTX-M-14 and TEM-1, confers greatly reduced in vitro sensitivity to avibactam, which we attribute to elevated conformational flexibility of the inhibitor within the active site. The findings presented in this study underpin the gatekeeper residue as a possible mutational hotspot and might aid the design of novel β-lactamase inhibitors.
β-内酰胺酶具有非凡的适应潜力,从而使许多β-内酰胺类药物失效。安布勒位置105处的残基,也被称为守门人残基,在底物识别中起重要作用,但其在抑制机制中的作用仍未得到充分研究且尚不明确。为了探究耐药表型与该位置残基之间的关系,我们利用深度测序对五种不同的A类β-内酰胺酶进行了位点饱和诱变和广泛的适应性分析。我们发现耐药性很容易检测到,含有甘氨酸或精氨酸的变体对抑制剂最不敏感。β-内酰胺酶BlaC中Ile105突变为Arg同时增强了对羧苄青霉素的活性以及逃避克拉维酸抑制的能力。在两种临床重要酶CTX-M-14和TEM-1中,Y105G替代使对阿维巴坦的体外敏感性大大降低,我们将其归因于活性位点内抑制剂构象灵活性的提高。本研究中的发现支持守门人残基作为一个可能的突变热点,并可能有助于新型β-内酰胺酶抑制剂的设计。